Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Aspen Pharmacare

This page shows the latest Aspen Pharmacare news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing

Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... The five generic medicines - chlorambucil,

Latest news

  • GSK sells another chunk of South Africa's Aspen GSK sells another chunk of South Africa's Aspen

    Paid $418m for an 18% share in Aspen in 2009.  . GlaxoSmithKline (GSK) has cashed in part of its holding in South Africa's Aspen Pharmacare, raising cash to help fund the ... We continue to believe in the strategy of Aspen and we remain committed to

  • Publicis boosts South Africa presence Publicis boosts South Africa presence

    The agency has 80 staff and works with blue-chip clients such as Aspen Pharmacare, Tanqueray Gin and TOTAL.

  • GSK cashes in its stake in Africa's Aspen GSK cashes in its stake in Africa's Aspen

    Sells 28.2 million shares. GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a "close relationship" with the South African company. ... Aspen's shares dipped nearly 4 per cent on news of the divestment.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    it offloaded several other products to to Aspen Pharmacare for £164m.

  • Tibotec HIV drug approved

    Aspen Pharmacare allowing them to manufacture, market and distribute the generic drug. ... Matrix and Hetero will have the rights to market the product in sub-Saharan Africa, certain developing countries and India, while Aspen will have rights to market

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.

  • Pharma deals during September 2013 Pharma deals during September 2013

    GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker. ... This agreement provides Aspen with the opportunity to expand into Russia and the CIS.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Quick links

Infographics

Multimedia